Updates in Management of Thalassemia Intermedia

Disease Classification And Core Principles

Thalassemia intermedia is currently classified as non-transfusion-dependent thalassemia (NTDT).
Patients exhibit moderate anemia with hemoglobin levels maintained between 7 to 10 g/dL without requiring lifelong regular transfusions.
Major morbidities arise from ineffective erythropoiesis, silent iron overload secondary to increased intestinal absorption, extramedullary hematopoiesis (EMH), hypercoagulability, and osteoporosis.
Modern management protocols prioritize individualized, complication-driven care over routine blanket transfusions.

Hydroxyurea remains the foundational first-line therapy for the majority of pediatric NTDT cases.
Recommended initiation dosing is 15 to 20 mg/kg/day.
The drug functions by boosting fetal hemoglobin (HbF) levels while actively suppressing ineffective erythropoiesis and EMH.
Indian pediatric cohorts demonstrate a 60 to 70% response rate, manifesting as a hemoglobin rise of at least 1 g/dL, particularly in HbE/β-thalassemia genotypes.

Mechanism: Induces fetal hemoglobin (HbF) to bind excess alpha-globin, reducing red blood cell destruction
Efficacy: ~63% of transfusion-dependent patients achieve complete transfusion independence.
Utility: A cheap, accessible alternative when stem cell transplants or gene therapies are unavailable.
Dosage: Starts at low doses (e.g., 50 mg/day) and is usually paired with aspirin to prevent blood clots.
Risks: Causes severe birth defects (strict contraception mandatory), nerve damage (requires routine monitoring), and drowsiness.

Mechanism: Promotes late-stage red blood cell maturation by blocking TGF- $β$ signaling.
Efficacy: Significantly reduces the number of transfusions needed and raises hemoglobin levels.
Utility: FDA-approved to lower transfusion burden and help prevent iron overload.
Dosage: Administered via subcutaneous injection once every 3 weeks.
Risks: Causes fatigue, bone pain, high blood pressure, and carries a risk for blood clots.

Mitapivat, an experimental pyruvate kinase activator, demonstrates emerging efficacy for hemoglobin gains in highly specific genotypes.

Routine, scheduled transfusions are avoided to prevent iatrogenic iron overload.
Transfusions are strictly reserved for objective growth faltering, severe symptomatic anemia, or acute life-threatening complications.

Deferasirox serves as the preferred oral iron chelator.
Chelation initiation is strictly threshold-driven, commencing only when serum ferritin persistently exceeds 800 ng/mL or Liver Iron Concentration (LIC) exceeds 5 mg/g dry weight.
Surveillance for iron deposition heavily prioritizes MRI T2* imaging performed every 6 to 12 months.

Routine splenectomy is actively avoided due to a 4 to 10-fold increased risk of severe thrombosis in NTDT patients.
Splenectomy remains reserved exclusively for severe hypersplenism following comprehensive immunization.
Standardized annual surveillance mandates MRI to track EMH and iron burden, alongside DEXA scanning for osteoporosis evaluation.
Comprehensive endocrine screening is initiated universally at 10 years of age.

Clinical care is governed by the Indian Academy of Pediatrics Pediatric Hemato-Oncology (IAP-PHO) 2023 guidelines and the Indian Society of Haematology & Blood Transfusion (ISHBT) 2026 recommendations.
The Ministry of Health and Family Welfare (MoHFW) integrates NTDT into state programs, providing free hydroxyurea and deferasirox via Centres of Excellence.
The National Policy for Rare Diseases (NPRD) provides financial support up to 20 lakh rupees for advanced therapies in eligible pediatric cohorts.